Academic Journal
Q2Journal of Pharmacology and Experimental Therapeutics
About Journal of Pharmacology and Experimental Therapeutics
Journal of Pharmacology and Experimental Therapeutics is a scholarly journal published by Elsevier Inc.. SCImago 2025 places it in Q2 with an SJR of 0.921 and an H-index of 254.
Its listed coverage is 1943, 1945-2026 and its research categories include Molecular Medicine (Q2); Pharmacology (Q2). The 2025 dataset reports 287 documents and 1418 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Receptor Mechanisms and Signaling, Neuroscience and Neuropharmacology Research, Neurotransmitter Receptor Influence on Behavior, Neuropeptides and Animal Physiology, Ion channel regulation and function, Diverse Scientific and Economic Studies.
Recent Research Articles
Latest publications matched automatically by ISSN.
Mitochondrial proteomic signatures of postcardiac arrest brain injury reveal potential therapeutic targets
Yankang Ren, Xinhui Fan, Ping Gong, Xianfei Ji et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105009Repurposing ribavirin for oncology: Integrating metabolism, signaling, and translational control
Amrita Talukder Mohini, Chibuike Emmanuel Okafor, Joseph M. Schober, Bhargav A. Patel et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105001Aryl hydrocarbon receptor as a molecular mediator in the induction of human aldehyde oxidase gene expression
Szu Ling Yeap, Cassandra Ching Lin Yap, Shi Han Tay, Linghua Harris Zhang et al.
2026-09 · DOI: 10.1016/j.jpet.2026.104993C5aR2 signaling mechanisms via the β-arrestin-dependent pathway observed in microsecond-scale MD simulations
Paulina Dragan, Dorota Latek
2026-09 · DOI: 10.1016/j.jpet.2026.105028Translational Pharmacokinetic/Pharmacodynamic Modeling to Inform Target Concentration and Dose Projection of A Novel Selective Estrogen Receptor Degrader (SIM0270) for Early Clinical Development
Yufei Shi, Meng Gu, Yang Yang, Shansen Xu et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105025RRx-001 sensitizes triple-negative breast cancer cells to oxaliplatin through apoptosis, cell cycle arrest, and immune modulation
Rafid K. Al-Fatlawi, Wrood S. AL-khfajy
2026-09 · DOI: 10.1016/j.jpet.2026.104992BE2012 a novel, REV-ERB antagonist that promotes regenerative myogenesis in vivo with substantially improved pharmacokinetics relative to SR8278
Isabelle Cote, Aurore C. Valfort, Ryan K. Sanders, Sheryl L. Burris et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105011CircDOPEY2 promotes prostate cancer metastasis via inhibiting heterogeneous nuclear ribonucleoprotein M ubiquitination to stabilize intercellular adhesion molecule 2 mRNA
Dingchang Shao, Yufeng Song, Jinke Liu, Mingkun Zhao et al.
2026-09 · DOI: 10.1016/j.jpet.2026.104995Circular RNAs regulate the progression of pulmonary hypertension through distinct roles and mechanisms
Gui-Feng Lu, Yao Guo, Fei Geng
2026-09 · DOI: 10.1016/j.jpet.2026.104987Prior Toll-like receptor 3 stimulation abolishes the ability of a MAPK/ERK kinase inhibitor to increase lipopolysaccharide-induced nitric oxide production concomitant with tumor necrosis factor-α suppression
Ryota Hashimoto, Yaojia Wu, Kaily Fujimoto, Haruto Shintani et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105013Neuromodulatory properties of thiopyrano[2,3-d]thiazole Les-2769: in silico and in vitro GABA/glutamatergic neurotransmission studies
Nataliya Pozdnyakova, Marina Dudarenko, Serhii Holota, Dmytro Khylyuk et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105026Impact of Δ9-tetrahydrocannabinol and oxycodone coadministration on measures of antinociception, dependence, circadian activity, and reward in mice
Richard A. Slivicki, Justin G. Wang, Kayla V. Kucz, Jakayla Folarin Hines et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105008Bioactivatable Conjugated Nanocarriers for Synergistic mRNA-Mediated Cancer Immunotherapy
Noman Nazir, Tushar B. Gajjar, Malathi Hanumanthayya, Neeraj Bainsal et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105029US postmarketed drug removals: Analysis of discontinued and withdrawn drugs
Lilly Josephine Bindel, Roland Seifert
2026-09 · DOI: 10.1016/j.jpet.2026.104996Modafinil ameliorates sleep deprivation–induced memory impairment under acute hypobaric hypoxia via biphasic Cyp3a11 regulation and altered pharmacokinetics
Gang Zhao, Limin Meng, Yajuan Li, Hui Shen et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105007Association of Pyruvate Metabolism-Related Genes with Immune Infiltration and Prognostic Value in Lung Adenocarcinoma
Fei Wang, Qiong Liang, Xiaotian Liang, Ying Liang et al.
2026-09 · DOI: 10.1016/j.jpet.2026.105027Risk of liver adverse events with nivolumab/ipilimumab combination therapy for hepatocellular carcinoma: A disproportionality analysis based on the Food and Drug Administration Adverse Event Reporting System data base
Yujie Liu, Hao Yu, Yi Wang, Changjing Xu et al.
2026-09 · DOI: 10.1016/j.jpet.2026.104994Dynamic mechanistic dominance in fentanyl and polysubstance overdose: Implications for next-generation reversal
Michael Voronkov, George Milevich, John Abernethy
2026-09 · DOI: 10.1016/j.jpet.2026.105002Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults
David Wolinsky, Dhathri Srungaram, Alec Zhang, Catherine F. Moore et al.
2026-08 · DOI: 10.1016/j.jpet.2026.104984Blocking interleukin 33 reduces joint, systemic, and lung inflammatory responses in the combined collagen-induced arthritis-inhalant endotoxin exposure model
Jill A. Poole, Jacob L. Larsen, Geoffrey M. Thiele, Todd A. Wyatt et al.
2026-08 · DOI: 10.1016/j.jpet.2026.104983Reviews
Community Reviews
Version History
September 8, 2026 at 12:02 am
September 8, 2026